RT Journal Article
SR Electronic
T1 A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer –ACTOR Study–
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1741
OP 1747
VO 38
IS 3
A1 MITSUKUNI SUENAGA
A1 TAKASHI AKIYOSHI
A1 EIJI SHINOZAKI
A1 YOSHIYA FUJIMOTO
A1 SATOSHI MATSUSAKA
A1 TSUYOSHI KONISHI
A1 SATOSHI NAGAYAMA
A1 YOSUKE FUKUNAGA
A1 KAZUYOSHI KAWAKAMI
A1 TAKASHI YOKOKAWA
A1 TAKAHITO SUGISAKI
A1 MASASHI UENO
A1 TOSHIHARU YAMAGUCHI
YR 2018
UL http://ar.iiarjournals.org/content/38/3/1741.abstract
AB Background/Aim: Past studies have suggested that adjuvant capecitabine and oxaliplatin (CAPOX) provides decreased tumor relapse and longer survival in patients with curatively resected colon cancer. We report the first evidence of the feasibility of adjuvant CAPOX in Japanese patients with early colon cancer. Patients and Methods: Eligible patients had histologically-confirmed stage II/III colon cancer and received curative resection. The primary endpoint was completion rate of treatment after 8 cycles of adjuvant CAPOX. Results: Thirty-six patients were enrolled in this study. The completion rate of CAPOX and oxaliplatin were 77.8% and 61.1%, respectively. The incidence of grade ≥3 adverse events was neutropenia (n=6), thrombocytopenia (n=3), nausea (n=5), hand-foot syndrome (n=1) and peripheral sensory neuropathy (n=1). Three-year disease-free survival for stage II patients and stage III patients were 100% and 79.3%, respectively. Conclusion: Adjuvant CAPOX can be safely administered to Japanese patients with stage II/III colon cancer.